Motley Fool Asset Management LLC Purchases 50,403 Shares of Bristol Myers Squibb Company $BMY

Posted by George Bondi on Jun 10th, 2026

Motley Fool Asset Management LLC boosted its position in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 30.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 216,468 shares of the biopharmaceutical company’s stock after acquiring an additional 50,403 shares during the period. Motley Fool Asset Management LLC’s holdings in Bristol Myers Squibb were worth $11,676,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in BMY. waypoint wealth counsel purchased a new stake in shares of Bristol Myers Squibb in the fourth quarter worth approximately $1,194,000. Life Cycle Investment Partners Ltd purchased a new stake in shares of Bristol Myers Squibb in the fourth quarter worth approximately $34,406,000. Axxcess Wealth Management LLC raised its stake in shares of Bristol Myers Squibb by 27.4% in the fourth quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock worth $5,322,000 after purchasing an additional 21,196 shares during the last quarter. M&G PLC raised its stake in shares of Bristol Myers Squibb by 1.4% in the third quarter. M&G PLC now owns 6,885,188 shares of the biopharmaceutical company’s stock worth $309,833,000 after purchasing an additional 97,063 shares during the last quarter. Finally, Daytona Street Capital LLC purchased a new stake in shares of Bristol Myers Squibb in the fourth quarter worth approximately $1,362,000. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

Shares of BMY opened at $56.43 on Wednesday. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. The company has a market capitalization of $115.23 billion, a price-to-earnings ratio of 15.85, a PEG ratio of 0.16 and a beta of 0.24. The stock has a 50 day moving average of $57.98 and a 200 day moving average of $56.73. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The company had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.Bristol Myers Squibb’s revenue was up 2.6% on a year-over-year basis. During the same period last year, the business posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts forecast that Bristol Myers Squibb Company will post 6.32 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently commented on BMY shares. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Bank of America lowered their price objective on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a research note on Thursday, April 9th. Guggenheim reissued a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Finally, Barclays started coverage on Bristol Myers Squibb in a research note on Thursday, February 19th. They issued an “overweight” rating and a $75.00 price objective for the company. Eight investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $61.31.

Read Our Latest Report on BMY

Insider Activity at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.05% of the company’s stock.

About Bristol Myers Squibb

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.